

# CURRENT THINKING IN HAEMATOLOGICAL MALIGNANCIES

## Challenges and Recurring Themes at MDT

.... a case-based MDT meeting

Friday 25<sup>th</sup> June 2021

**Manchester International Conference Centre  
3 Hardman Square, Manchester M3 3EB**

The speaker panel will be on-site in Manchester for this meeting and are looking forward to meeting the local haematology community

09.30 *Registration*

10.00 **Myeloma**

**Chair: Graham Jackson (Newcastle)**

Panel: Graham Jackson, Chris Parrish (Leeds) & TBC

Myeloma MDT

- Treatments for the elderly patients - dilemmas and difficult cases
- Treatment dilemmas: cases at first relapse
- Treatment dilemmas: cases at late relapse

11.00 **Chronic Leukaemia**

**Chair: Piers Patten (London)**

Panel: Piers Patten, George Follows (Cambridge) & Anne Parker (Glasgow)

Different CLL situations in vignette:

Frontline, relapse and a high-risk allograft

11.45 *Coffee*

12.00 **Acute Leukaemia**

**Chair: Mike Dennis (Manchester)**

Panel: Annie Latif (Glasgow) & Rachel Protheroe (Bristol)

Approach to the newly diagnosed patient - intensive versus venetoclax-based therapies

Questions (5 mins)

Which AML should be transplanted in CR1?

Questions (5 mins)

Round table discussion

12.45 **Questions arising from the morning sessions**

13.00 *Lunch*

13.30 **Lymphoma Carousel**

**Chair: Tim Illidge (Manchester)**

Panel: Tim Illidge, Wendy Osborne (Newcastle), Andrew McMillan (Nottingham) & Tobias Menne (Newcastle)

- Challenging T cell lymphoma cases
- Commissioning changes during COVID, what treatments can be given earlier?
- How should we use BR polatuzumab?
- Using bispecific antibodies and considering optimal sequencing of therapies in follicular and mantle cell lymphoma
- Should we consider CAR T or allo for relapsed refractory mantle cell lymphoma?
- How should we approach bridging patients to CAR T?

*Continued over page*

15.30 *Coffee*

15.50 **ALL Discussion MDT Panel**

**Chair: Andrew McMillan (Nottingham)**

Panel: Andrew McMillan, Tobias Menne (*Newcastle*) & Anna Castleton (*Manchester*)

- Pre-transplant intervention for MRD positive patients - will this improve outcomes?
- The end of the road for chemotherapy salvage therapies in second line therapy of ALL?
- Adult versus paediatric & young adult strategies in ALL - how young is young?
- Addition of rituximab to standard of care in ALL - better late than never?

16.30 **MDT Panel: When is an allograft appropriate**

**Chairs: Anne Parker (Glasgow) & Wendy Osborne (Newcastle)**

- |   |                |
|---|----------------|
| 1. Donor choice                                     | Anne Parker    |
| 2. MM - double auto v auto/allo for a young patient | Graham Jackson |
| 3. Older ALL - MRD positive                         | Tobias Menne   |
| 4. Age 65 - myelofibrosis                           | Fiona Dignan   |

17.30 *Close*

**Registration Fees:**

**Consultants: £40 + VAT**

**Trainees, Nurses, AHPs: £30 + VAT**

Register on-line at [www.hartleytaylor.co.uk](http://www.hartleytaylor.co.uk) or  
contact Alex [alex@hartleytaylor.co.uk](mailto:alex@hartleytaylor.co.uk) for further information

*This meeting will be live streamed for those who are unable to travel into Manchester.  
Please make sure to select the appropriate package during the registration process.*

